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Abstract
Background—Persons who inject drugs (PWID) are at high risk for acquiring hepatitis C virus 
(HCV) infection. The Centers for Disease Control and Prevention estimates there are 17 000 new 
infections per year, mainly among PWID. This study examines injection equipment serosorting—
considering HCV serostatus when deciding whether and with whom to share injection equipment.
Objective—To examine whether injection equipment serosorting is occurring among PWID in 
selected cities.
Methods—Using data from the National HIV Behavioral Surveillance System-Injection Drug 
Users (NHBS-IDU2, 2009), we developed multivariate logistic regression models to examine the 
extent to which participants’ self-reported HCV status is associated with their injection equipment 
serosorting behavior and knowledge of last injecting partner’s HCV status.
Results—Participants who knew their HCV status were more likely to know the HCV status of 
their last injecting partner, compared to those who did not know their status (HCV+: adjusted odds 
ratio [aOR] 4.1, 95% confidence interval [CI], 3.4–4.9; HCV−: aOR 2.5, 95% CI, 2.0–3.0). 
Participants who reported being HCV+, relative to those of unknown HCV status, were 5 times 
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more likely to share injection equipment with a partner of HCV-positive status (aOR 4.8, 95% CI, 
3.9–6.0).
Conclusions—Our analysis suggests PWID are more likely to share injection equipment with 
persons of concordant HCV status.
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The Centers for Disease Control and Prevention (CDC) estimates that 4.1 million Americans 
have been infected with the hepatitis C virus (HCV) with 75%–80% of those chronically 
infected [1]. While CDC recommends routine antibody testing for persons at risk of HCV 
exposure [2], recent studies estimate 40%–85% of HCV-infected persons are unaware of 
their infection status [3–5]. This lack of awareness has important consequences for disease 
prevention because knowledge of HCV status is often a prerequisite to making health-
promoting behavioral changes and treatment decisions.
HCV prevalence has reached epidemic proportions in the United States and is endemic 
among persons who inject drugs (PWID). HCV is primarily by percutaneous exposure to 
contaminated blood, making injection drug use (IDU) the leading cause of incidence in the 
United States. HCV prevalence among PWID resides between 30% and 70%, depending on 
frequency and duration of use, and incidence ranges from 16%–42% per year [6–8].
With such high prevalence of infection, recent attention has focused on factors that influence 
a person’s decision to share or not to share injection equipment (IE). One such factor is 
serostatus, particularly the question as to whether knowing one’s HCV status, and that of a 
prospective partner, affects a person’s decision to share IE. We suggest the complex 
relationship between a person’s serostatus and their decision to share IE can be illuminated, 
in part, through the concept of serosorting.
Serosorting occurs when viral serostatus serves as a determining factor in a person’s choice 
of sex or drug-injecting partners and in the selection of behaviors stemming from that 
choice. The term has traditionally been used to describe men who have sex with men 
(MSM), who deliberately select sex partners based on their own and their prospective 
partner’s human immunodeficiency virus (HIV) serostatus [9]. Here, serostatus is 
characterized as a type of measure whereby people choose a sexual partner based on their 
own and their partner’s HIV status and then base the extent of their sexual activity on that 
knowledge for the specific purpose of reducing the risk of acquiring or transmitting HIV.
While serosorting has been used most notably to describe the sexual choices of MSM, 
researchers have recently found similar trends among PWID [10–12]: one study in Seattle 
reported PWID were more likely to share injection equipment with the last injecting partner 
of concordant status [10]; an investigation in San Francisco found those who perceived their 
injecting partner to be HCV-positive were less likely to engage in receptive needle sharing 
[11]; and in Baltimore, HIV-positive participants reported being less likely to serosort than 
HIV-negative participants [12]. Bearing in mind these city-specific trends, this study 
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expands their scope by examining injection equipment serosorting among PWID on a 
national scale. Specifically, we examine the relationships between participant’s self-reported 
HCV status and (a) injection equipment sharing behavior, (b) knowledge of last injecting 
partner’s HCV status (known/unknown), and (c) last injecting partner’s HCV status 
(positive/negative).
METHODS
National HIV Behavioral Surveillance System (NHBS)
NHBS is a community-based survey that conducts interviews in triennial cycles among 
MSM, heterosexuals at increased risk for HIV infection, and PWID. Its purpose is to track 
the prevalence of and trends in HIV-related risk behaviors, including sex and injection drug 
use, and to record levels of HIV testing and the use of HIV prevention services among 
persons at high risk for HIV transmission such as PWID [13]. The second IDU cycle 
(NHBS-IDU2) was conducted between September and December 2009 and employed 
respondent-driven sampling (RDS) [14] to target individuals from social networks that can 
serve as seeds to recruit their peers into the study. Participating sites included in this analysis 
were located in Atlanta, Baltimore, Boston, Chicago, Dallas, Denver, Detroit, Houston, Los 
Angeles, Miami, Nassau, Newark, New Orleans, New York, Philadelphia, San Diego, San 
Francisco, San Juan, Seattle, and Washington, DC. Across the 20 sites, 10 352 respondents 
were eligible for NHBS-IDU2 and participated in the study. The current study was restricted 
to 9690 participants with valid responses to questions concerning their HCV status and the 
HCV status of their last injection equipment sharing partner within the previous 12 months.
Outcome Measures
The outcomes of interest were (a) injection equipment sharing behavior, (b) knowledge of 
last injecting partner’s HCV status (known/unknown), and (c) last injecting partner’s HCV 
status (positive/negative). The HCV status of respondent and respondent’s last injecting 
partner were both self-reported by the respondent. The HCV status of respondent’s last 
injection partner was derived from the following questions: “The last time you injected with 
this person (last sharing partner in past 12 months), did you know if they had been tested for 
hepatitis C?” and if yes, “What was the result of their hepatitis C test?” Respondents were 
also asked a series of questions with respect to their injection equipment sharing behaviors 
over the previous 12 months. Equipment sharing was defined to include the reuse of 
syringes, filters, cookers, water, and the practice of dividing drugs with a syringe (eg, 
backloading or frontloading). We categorized equipment sharing behavior in 2 different 
ways. For exploratory bivariate analysis, we dichotomized this variable as shared vs did not 
share. We also categorized the same outcome as a 4-level multinomial response variable for 
subsequent advanced analysis: shared with HCV-negative partner, shared with HCV-positive 
partner, shared with partner of unknown HCV status, or shared no injection equipment.
Independent Variables
The primary independent variable was respondent’s HCV status. Based on a review of the 
literature regarding HCV and injection equipment sharing, we also included the following 
variables as confounders and/or independent predictors: respondent’s gender, race/ethnicity, 
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birth year (as proxy for age), education, homelessness, employment status, annual income, 
age at first injection, and duration of injection.
Data Analysis
We calculated unweighted proportions to describe the characteristics of the study population. 
Pearson χ2 tests were used to explore bivariate associations between all independent 
variables and outcome variables. Consistent with the stated objectives of this study, we 
developed 3 separate multivariate logistic regression models to evaluate the associations 
between the respondent’s HCV status and the 3 outcome measures, adjusting for all 
plausible confounders. First, we modeled equipment sharing (4-level response category) as 
the dependent variable in a multinomial logistic regression; participants who shared 
equipment with their last injecting partner of negative, positive, or unknown HCV status 
were compared to those who did not share. This model was based on the full analytic 
population (n = 9690). In the second model, we restricted our analysis to respondents who 
reported sharing equipment (n = 4542) and modeled respondent’s knowledge of last 
injecting partner’s HCV status (known/unknown) as the dependent variable. In the third 
model, we further restricted the analysis to respondents who reported awareness of their last 
injecting partner’s HCV status (n = 1712), and modeled last injection partner’s HCV status 
(positive/negative) as the dependent variable. In all 3 models, respondent’s HCV status was 
the primary explanatory variable. Data were analyzed using SPSS v.18 (IBM, Chicago, IL). 
We did not account for potential variance inflation induced by the RDS design, due to the 
limitation of the statistical software used; RDS is a relatively new methodology and is not 
currently incorporated into multivariate procedures available in standard statistical software.
RESULTS
Of the NHBS-IDU2 participants, 9690 respondents self-reported both their HCV status and 
the HCV status of their last injecting partner. Of all participants, 7270 (75.0%) reported 
knowing their HCV status and 4128 (56.8%) of those reported HCV positivity. Nearly 47 
percent of all participants (n = 4542) reported sharing equipment with their last injecting 
partner in the previous 12 months, and of those 37.7% (n = 1712) said they were aware of 
the HCV status of their last sharing partner. The demographic characteristics of participants 
are shown in Table 1. Approximately 71.8% were male, 21.6% Hispanic, 46.8% non-
Hispanic black, and 27.1% non-Hispanic white. Respondents were born between 1930 and 
1991, with a mean of 1963 (ie, approximately 46 years of age). About 13.3% of respondents 
were employed, 57.3% were unemployed, and 24.1% were disabled for work. More than 
61% of respondents reported ever being homeless, and 32.1% reported injecting before the 
age of 18 years.
Association Between Participant’s HCV Status and Sharing Equipment With Last Injection 
Partner
In bivariate analysis, all independent variables, with the exception of injection duration, 
were significantly associated with participant’s equipment sharing behavior (Table 1). 
Following multivariate adjustment in a multinomial logistic regression, HCV-negative 
participants, compared to those of unknown HCV status, were more likely to share 
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equipment with an HCV-negative injecting partner vs not sharing (adjusted odds ratio [aOR] 
2.0, 95% confidence interval [CI], 1.6–2.6) (Table 2). Similarly, the odds of sharing with an 
HCV-positive partner, vs not sharing, is increased nearly 5-fold (aOR 4.8, 95% CI, 3.9–6.0) 
for HCV-positive participants relative to those of unknown HCV status. In contrast, 
respondents with known HCV status, compared to those of unknown HCV status, were less 
likely to share with a partner of unknown HCV status vs not sharing (HCV-positive: aOR .8, 
95% CI, .7–.9; HCV-negative: aOR .6, 95% CI, .5–.7). Other variables found to be 
significantly related to injection equipment sharing behavior after multivariate adjustment 
were gender, race/ethnicity, birth year, education, history of homelessness, employment, and 
age at first injection (Table 2).
Association Between Participant’s HCV Status and Knowledge of Sharing Partner’s HCV 
Status
The results of multivariate logistic regression analysis examining the relationship between 
participant’s self-reported HCV status and knowledge of last injecting partner’s HCV status 
are presented in Table 3. Among respondents who shared injection equipment, those who 
knew their HCV status were more likely to know their last injecting partner’s HCV status 
compared to those with unknown HCV status: HCV-negative participants (aOR 2.5, 95% CI, 
2.0–3.0) were more than 2 times and HCV-positive participants (aOR 4.1, 95%CI, 3.4–4.9) 
were more than 4 times more likely to have knowledge of their last partner’s HCV status 
compared to respondents who reported an unknown HCV status. Female gender, non-
Hispanic white race/ethnicity, educational attainment of high school or more, disabled 
status, and higher annual income were also positively associated with knowledge of last 
partner’s HCV status. Non-Hispanic black race/ethnicity and history of homelessness were 
associated with lack of knowledge of last partner’s HCV status.
Association Between Participant’s HCV Status and Sharing Partner’s HCV Status
Table 4 shows the results of a multivariate logistic regression model examining the 
association between participant’s self-reported HCV status and last injecting partner’s HCV 
status. Among the respondents who shared injection equipment and reported knowing their 
last injecting partner’s HCV status, HCV-positive persons (aOR 4.6, 95% CI, 3.2–6.4) were 
nearly 5 times more likely to report their last injecting partner’s HCV status as positive 
relative to persons with an unknown HCV status. By comparison, HCV-negative persons 
(aOR .4, 95% CI, .3–.6) were 60% less likely to report their last injecting partner’s HCV 
status as positive relative to persons with an unknown HCV status. Non-Hispanic black 
participants were less likely to report their injecting partner’s HCV status as positive 
compared to Hispanics. Participants with a history of homelessness and those born from 
1930 to 1954, respectively, were more likely to report their injecting partner as HCV positive 
relative to persons who had never been homeless and those born between 1975 and 1991.
DISCUSSION
The strong association between the HCV status of survey respondents and the HCV status of 
their last injection partner is evidence indicating that PWID are injection equipment 
serosorting. Our analysis found that PWID are injection equipment serosorting given that 
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study participants were more likely to share injection equipment (IE) with people of 
concordant HCV status. This outcome corroborates earlier findings demonstrating a 
correlation between a person’s awareness of his/her HCV status and choice of injecting 
partners [10].
Serosorting is well documented in the literature but largely in the context of HIV risk 
reduction. Researchers focusing on the sexual choices of MSM [15, 16] have found 
serosorting is associated with decreased risk of HIV infection [17] and changes in the sexual 
behavior of MSM when it is employed as an HIV risk-reduction strategy [18]. Serosorting 
has also been documented among HIV-positive PWID [19]. They have been shown to be 
more likely to disclose their infection status to other infected persons and more likely to seek 
out concordant drug-using relationships [12] than HIV-negative persons. HIV-positive PWID 
in serodiscordant sexual relationships were also found to be more likely to modify their 
injecting and sexual behavior than participants who were HIV-negative [20] and less likely 
to engage in less safe drug use and risky sexual behaviors [21]. These findings demonstrate 
that PWID have the capacity to employ risk reduction behaviors meant to protect their health 
and that of their injection partners [22, 23].
In this way, serosorting can be applied to drug injection behavior when the act of choosing 
an injecting partner is based in part on one’s own infection status and that of the prospective 
injecting partner’s for the specific purpose of reducing the risk of acquiring or transmitting 
bloodborne pathogens during an injection episode. Here, serosorting can be categorized as a 
risk-reduction strategy when the decision to share or not to share injection equipment is 
influenced by serostatus and enacted by people unable or unwilling to cease injecting drugs, 
but who nevertheless want to protect their and their injecting partner’s health when injecting 
drugs together. Following this logic, both the act of selecting an injecting partner of 
concordant infection status and the act of avoiding sharing injection equipment with a 
person of discordant infection status would be categorized as injecting equipment 
serosorting [24].
The hepatitis C literature provides a modicum of evidence that knowledge of one’s own or 
another’s HCV status can influence how or with whom people inject. One study in Seattle 
reported PWID were more likely to share injection equipment with the last injecting partner 
of concordant status [10], while in San Francisco those who perceived their injecting partner 
to be HCV-positive were found to be less likely to engage in receptive needle sharing [11]; 
and in Baltimore, HIV-positive participants reported being less likely to injection equipment 
serosort than HIV-negative participants [12]. The evidence, however, is not entirely positive. 
Numerous studies show that knowledge of one’s HCV status has nominal influence on 
reducing behaviors that put PWID at risk for acquiring or transmitting bloodborne disease 
[25–27]. A study of young PWID found no association between HCV-positive status and 
reductions in less safe injecting practices or choice of injecting partners [28], and another 
found injecting partners not discriminating based on serostatus and sharing injection 
equipment just as frequently with sexual partners of concordant and discordant status [29].
This variation notwithstanding, our analysis of the NHBS-IDU2 data establishes a strong 
association between a survey respondent’s knowledge of their HCV status and the selection 
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of an injecting partner. This correlation is deduced from 4 significant findings: (1) a person 
knowing their HCV status was more likely to know their last injection partner’s HCV status; 
(2) a person knowing their HCV status was less likely to share injection equipment with a 
partner of unknown HCV status; (3) a person knowing their HCV-negative status was more 
likely to share injection equipment with a partner that was also HCV-negative; (4) a person 
knowing their HCV-positive status was more likely to share equipment with a partner 
reporting an HCV-positive status. These findings suggest that PWID may be serosorting by 
selectively sharing injecting equipment with persons of corresponding HCV status.
This article is not intended to promote injection equipment serosorting as a HCV risk-
reduction strategy for PWID but to report that participants were more likely to share 
syringes with persons of concordant serostatus. One problem that can be expected if 
injection equipment serosorting is adopted by PWID is the potential effect of incomplete 
knowledge of infection status. If PWID know they are anti-HCV positive but mistakenly 
believe they are infected (when they have actually cleared the virus and are negative for 
HCV RNA), they could opt to serosort injection equipment with infected persons based on 
this misunderstanding, placing themselves at risk. This issue highlights the importance of 
conducting HCV RNA tests for all HCV antibody-positive persons and ensuring that they 
receive and understand their results.
A similar challenge that arises when PWID serosort by injection equipment is the injecting 
partner’s knowledge of their own HCV status. This requires both accurate knowledge and 
understanding by the injection partner and full disclosure of their HCV status. Although 
there are proven effective HIV testing and counseling interventions [30], as well as effective 
interventions to improve disclosure skills for HIV-positive persons [31], there are no HCV-
specific interventions to improve either of these factors. Much can be learned from these 
established interventions, but HCV test results and counseling messages and disclosure 
issues require more nuanced communication given the 2-step testing process to determine 
HCV-infection status and the knowledge needed to understand and disclose that information 
to injection partners.
This study has some limitations. Unlike several previous studies of serosorting [10], the 
national data collected through the NHBS-IDU2 study did not include information regarding 
participants’ intention to serosort. It thus remains unknown if the high level of serosorting 
observed in this study was driven by an intention to do so. Further research needs to be 
conducted to explore whether intention to serosort is based on the HCV infection status of 
self and other, and what other factors may be contributing to this behavior. Additional 
limitations were related to the participant recruitment. The lack of adjustment for the design 
effect of RDS may have resulted in biased prevalence estimates and artificially smaller 
standard errors in bivariate analysis; however, there is no consensus on the statistical 
methods for conducting multivariate analysis [32–37]. Moreover, participants’ and their 
partners’ HCV status were self-reported and do not represent actual prevalence, and 
injecting equipment serosorting behavior is based on participants’ perceived HCV status. 
Future research should thus include analyses of serosorting behavior based on actual vs 
perceived HCV status. Finally, given the unexplained differences in knowledge of serostatus 
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by gender, race, educational attainment, and homelessness, additional research should be 
conducted to examine these issues fully.
CONCLUSION
Our analysis of the NHBS-IDU2 data points to the possibility that PWID are serosorting 
based on knowledge of their and their injecting partners’ HCV status. If accurate, the ability 
to increase PWID’s awareness of their HCV status will have important consequences for 
public health and disease prevention, as it could be an influential element in a person’s 
decision to make health-promoting behavioral changes and their choice of medical 
treatment. In sum, increasing the proportion of PWID who are aware of their HCV status 
may contribute to a general increase in the adoption of risk reduction strategies by persons 
who inject drugs.
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Table 2
Adjusted Odds Ratios for the Association Between Participant’s Self-reported HCV Status and Injection 
Equipment Sharing Behavior, NHBS Injection Drug Users Second Cycle (N = 9612a), 2009
Participant Characteristic
Shared With HCV(−) Partner 
vs No Sharing
Shared With HCV(+)Partner vs 
No Sharing
Shared With HCV (Unknown) 
Partner vs No Sharing
Adjustedb OR (95% CI) Adjustedb OR (95% CI) Adjustedb OR (95% CI)
Self-reported HCV status
 Negative 2.0 (1.6, 2.6)c .8 (.6, 1.1) .6 (.5, .7)c
 Positive 1.1 (.9, 1.5) 4.8 (3.9, 6.0)c .8 (.7, .9)c
 Unknown Ref Ref Ref
Gender
 Female 1.7 (1.4, 2.0)c 1.7 (1.5, 2.0)c .9 (.8, 1.0)
 Male Ref Ref Ref
Race/ethnicity
 Black .8 (.7, 1.1)
.6 (.5, .7)c 1.2 (1.1, 1.4)d
 White 1.1 (.9, 1.4) 1.1 (.9, 1.4) .8 (.7, .9)
 Hispanic Ref Ref Ref
Birth year
 1930–1944 .4 (.1, 1.0) .7 (.3, 1.5)
.4 (.2, .7)c
 1945–1954
.5 (.3, .8)d .8 (.5, 1.2) .6 (.5, .8)c
 1955–1964
.5 (.3, .7)c .9 (.6, 1.2) .8 (.6, 1.0)e
 1965–1974
.7 (.5, .9)e 1.0 (.8, 1.3) .9 (.8, 1.1)
 1975–1991 Ref Ref Ref
Educational attainment
 High school graduate 1.2 (1.0, 1.4) 1.0 (.9, 1.2)
.8 (.7, .9)c
 Less than high school Ref Ref Ref
Ever homeless
 Yes 1.2 (1.0, 1.5)e 1.7 (1.5, 2.0)c 1.9 (1.7, 2.1)c
 No Ref Ref Ref
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Participant Characteristic
Shared With HCV(−) Partner 
vs No Sharing
Shared With HCV(+)Partner vs 
No Sharing
Shared With HCV (Unknown) 
Partner vs No Sharing
Adjustedb OR (95% CI) Adjustedb OR (95% CI) Adjustedb OR (95% CI)
Employment status
 Unemployed 1.2 (.9, 1.6) 1.2 (.9, 1.5) 1.1 (1.0, 1.3)
 Disabled 1.4 (1.0, 1.9) 1.3 (1.0, 1.7) .9 (.8, 1.1)
 Other 1.6 (1.0, 2.4)e .8 (.5, 1.2) .9 (.7, 1.1)
 Employed Ref Ref Ref
Age at first injection, years
 ≥25 .9 (.6, 1.2)
.7 (.5, .9)d 1.0 (.9, 1.2)
 18–24 .8 (.7, 1.1) .9 (.8, 1.1) 1.0 (.8, 1.1)
 <18 Ref Ref Ref
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; NHBS, National HIV Behavioral Surveillance System; OR, odds ratio.
a
Does not include n = 78 participants with missing data for at least one of the variables in the model.
b
Model adjusted for all variables shown in table plus participant’s income category and injection history duration.
c
<.001.
d
<.01.
e
<.05.
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Table 3
Adjusted Odds Ratios for the Association Between Participant’s Self-reported HCV Status and Knowledge of 
Last Injection Partner’s HCV Status, NHBS Injection Drug Users Second Cycle (N = 4506a), 2009
Participant Characteristic Adjustedb OR (95% CI) P Value
Self-reported HCV status
 Negative 2.5 (2.0, 3.0) <.001
 Positive 4.1 (3.4, 4.9) <.001
 Unknown Ref
Gender
 Female 1.8 (1.6, 2.1) <.001
 Male Ref . . .
Race/ethnicity
 Black .5 (.4, .6) <.001
 White 1.5 (1.2, 1.8) <.001
 Hispanic Ref . . .
Birth year
 1930–1944 .9 (.7, 1.1) .318
 1945–1954 .9 (.6, 1.2) .317
 1955–1964 1.0 (.7, 1.4) .914
 1965–1974 1.2 (.5, 2.6) .715
 1975–1991 Ref . . .
Educational attainment
 High school graduate 1.3 (1.1, 1.5) <.001
 Less than high school Ref . . .
Ever homeless
 Yes .8 (.7, .9) <.01
 No Ref . . .
Employment status
 Unemployed 1.0 (.8, 1.3) .727
 Disabled 1.5 (1.1, 1.9) <.01
 Other 1.3 (.9, 1.8) .225
 Employed Ref . . .
Annual income
 $15 000 or more 1.2 (1.0, 1.4) <.05
 $0–$14 999 Ref . . .
Age at first injection, years
 ≥25 .8 (.6, 1.0) .079
 18–24 .9 (.7, 1.0) .097
 <18 Ref . . .
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; NHBS, National HIV Behavioral Surveillance System; OR, odds ratio.
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a
Does not include n = 36 participants with missing data for at least one of the variables in the model.
b
Model adjusted for all variables shown in table plus participant’s injection history duration.
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Table 4
Adjusted Odds Ratios for the Association Between Participant’s Self-reported HCV Status and Last Injection 
Partner’s HCV Status, NHBS Injection Drug Users Second Cycle (N = 1698a), 2009
Participant Characteristic Adjustedb OR (95% CI) P Value
Self-reported HCV status
 Negative .4 (.3, .6) <.001
 Positive 4.6 (3.2, 6.4) <.001
 Unknown Ref . . .
Gender
 Female 1.1 (.8, 1.4) .539
 Male Ref . . .
Race/ethnicity
 Black .6 (.4, .8) <.01
 White 1.0 (.7, 1.3) .963
 Hispanic Ref . . .
Birth year
 1930–1944 1.6 (1.0, 2.4) <.05
 1945–1954 2.0 (1.2, 3.6) <.05
 1955–1964 1.8 (.9, 3.4) .088
 1965–1974 3.9 (.9, 17.3) .073
 1975–1991 Ref . . .
Educational attainment
 High school graduate .9 (.7, 1.1) .318
 Less than high school Ref . . .
Ever homeless
 Yes 1.5 (1.1, 1.9) <.01
 No Ref . . .
Employment status
 Unemployed .9 (.6, 1.4) .704
 Disabled .8 (.5, 1.3) .396
 Other .6 (.3, 1.0) .065
 Employed Ref . . .
Annual income
 $15 000 or more 1.1 (.8, 1.5) .398
 $0–$14 999 Ref . . .
Age at first injection, years
 ≥25 .7 (.4, 1.1) .122
 18–24 1.0 (.8, 1.4) .839
 <18 Ref . . .
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; NHBS, National HIV Behavioral Surveillance System; OR, odds ratio.
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a
Does not include n = 14 participants with missing data for at least one of the variables in the model.
b
Model adjusted for all variables shown in table plus participant’s injection history duration
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